Theriva Biologics

TOVX

Market cap $3.98M

Overview Fund Activity

0.4143 USD

-0.0010

0.24%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

0.4160

+0.0017

0.41%

1 day

-0.24%

5 days

5.99%

1 month

-10.52%

3 months

-11.3%

6 months

-65.18%

Year to date

-74.89%

1 year

-89.24%

5 years

-99.66%

10 years

-100%

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Employees: 22

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

60% more funds holding

Funds holding: 10 [Q1] → 16 (+6) [Q2]

3.64% less ownership

Funds ownership: 6.86% [Q1] → 3.22% (-3.64%) [Q2]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

39% less capital invested

Capital invested by funds: $210K [Q1] → $128K (-$82.2K) [Q2]

See Fund Rankings

Financial journalist opinion

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October -

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Theriva Biologics Announces Closing of $7.5 Million Public Offering

ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company received aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants have an exercise price of $1.10 per share, became exercisable immediately upon issuance and expire five years from the issuance date.

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately and will expire five years from the issuance date.

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company's Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 –

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva's management team will participate in 1x1 meetings.

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type D meeting with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC). The Company recently announced the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as a first line therapy for PDAC patients.

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

See News Rankings

Charts implemented using Lightweight Charts™